Resurgence of , including one macrolide-resistant isolate, France, 2024.
Carla Rodrigues, Val��rie Bouchez, Ana��s Soares, Sabine Trombert-Paolantoni, Fatima A��t El Belghiti, J��r��mie F Cohen, Nathalie Armatys, Annie Landier, Thomas Blanchot, Marie Hervo, REMICOQ study group, Julie Toubiana, Sylvain Brisse
Author Information
Carla Rodrigues: These authors contributed equally to this work and share first authorship.
Val��rie Bouchez: These authors contributed equally to this work and share first authorship.
Ana��s Soares: Laboratoire Eurofins Biomnis, Lyon, France.
Sabine Trombert-Paolantoni: Laboratoire Cerba, Saint Ouen l'Aum��ne, France.
Fatima A��t El Belghiti: Sant�� publique France, Infectious Diseases Department, The French Public Health Agency, Saint-Maurice, France.
J��r��mie F Cohen: Centre for Research in Epidemiology and Statistics (Inserm UMR 1153), Universit�� Paris Cit��, Paris, France.
Nathalie Armatys: National Reference Center for Whooping Cough and other Bordetella infections, Institut Pasteur, Paris, France.
Annie Landier: National Reference Center for Whooping Cough and other Bordetella infections, Institut Pasteur, Paris, France.
Thomas Blanchot: Laboratoire Eurofins Biomnis, Lyon, France.
Marie Hervo: Laboratoire Eurofins Biomnis, Lyon, France.
: The members of the REMICOQ study group are listed under Collaborators.
Julie Toubiana: These authors co-supervised the work and share last authorship.
Sylvain Brisse: These authors co-supervised the work and share last authorship.
As other European countries, France is experiencing a resurgence of pertussis in 2024. Between 1 January and 31 May 2024, 5,616 (24.9%) positive qPCR tests were identified, following a 3-year period of almost null incidence. Of 67 cultured and whole genome sequenced isolates, 66 produced pertactin and 56 produced FIM2, in contrast to pre-COVID-19 years. One isolate of genotype Bp-AgST4 was resistant to macrolides . Pertussis resurgence may favour isolates that produce FIM2 and pertactin.
Expert Rev Vaccines. 2014 Oct;13(10):1205-14
[PMID: 25102891 ]
mBio. 2014 Apr 22;5(2):e01074
[PMID: 24757216 ]
Euro Surveill. 2019 Feb;24(7):
[PMID: 30782265 ]
Proc Biol Sci. 2016 Jan 13;283(1822):
[PMID: 26763701 ]
Emerg Infect Dis. 2021 Jun;27(6):1561-1566
[PMID: 34014152 ]
Emerg Infect Dis. 2012 Jun;18(6):966-8
[PMID: 22608348 ]
Proc Natl Acad Sci U S A. 2005 Apr 5;102(14):5180-5
[PMID: 15795375 ]
Emerg Infect Dis. 2018 Jun;24(6):988-994
[PMID: 29774847 ]
Pediatr Infect Dis J. 2015 Aug;34(8):814-20
[PMID: 25955837 ]
BMC Public Health. 2022 Feb 28;22(1):405
[PMID: 35220973 ]
Rev Paul Pediatr. 2019 Jun 19;37(3):351-362
[PMID: 31116241 ]
J Med Microbiol. 2024 Jul;73(7):
[PMID: 38995835 ]
Nat Commun. 2022 Jul 1;13(1):3807
[PMID: 35778384 ]
Euro Surveill. 2021 Sep;26(37):
[PMID: 34533118 ]
Sci Transl Med. 2022 Apr 27;14(642):eabn3253
[PMID: 35476597 ]
BMJ. 2024 Jun 18;385:q1348
[PMID: 38889948 ]
Microbes Infect. 2023 Sep-Oct;25(7):105152
[PMID: 37245862 ]
Vaccine. 2009 Oct 9;27(43):6034-41
[PMID: 19666155 ]
Euro Surveill. 2022 Jun;27(25):
[PMID: 35748301 ]
Antibiotics (Basel). 2022 Nov 07;11(11):
[PMID: 36358225 ]
Bordetella pertussis
Humans
France
Macrolides
Whooping Cough
Anti-Bacterial Agents
Drug Resistance, Bacterial
Microbial Sensitivity Tests
Bacterial Outer Membrane Proteins
Whole Genome Sequencing
Virulence Factors, Bordetella
Genotype
Adult
Child
Incidence
Child, Preschool
Macrolides
Anti-Bacterial Agents
pertactin
Bacterial Outer Membrane Proteins
Virulence Factors, Bordetella
